• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

  • Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • Countering AMR
  • COVID-19 Research
  • Digital Therapies
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Patient Participation Awareness Week 2022

In recognition of National Patient Participation Week, OHE wants to acknowledge the integral role that patients and the public play in how decisions are made in the National Health Service (NHS) and other health systems. This includes decisions about their…

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for PolicymakersRead more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes
  • PhRMA

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
When Generic Measures Fail to Reflect What Matters to Patients: Three Case StudiesRead more
© NCI/Unsplash
  • Health Technology Assessment…
  • Measuring and Valuing Outcomes
  • Canada

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Cancer_WellcomeCollection_landscape
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic TherapiesRead more
© WellcomeCollection
Close
OHE
  • All Publications

    Filter by:
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • Countering AMR
    • COVID-19 Research
    • Digital Therapies
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 30th May 2022

Patient Participation Awareness Week 2022

In recognition of National Patient Participation Week, OHE wants to acknowledge the integral role that patients and the public play in how decisions are made in the National Health Service (NHS) and other health systems. This includes decisions about their…

Share:
patientcare_shutterstock_1190997985_landscape

In recognition of National Patient Participation Week, OHE wants to acknowledge the integral role that patients and the public play in how decisions are made in the National Health Service (NHS) and other health systems. This includes decisions about their own care but also decisions that can affect how and which services are provided to other patients or the wider population.

Patient feedback in primary care on the provision and quality of the care they receive and the treatments that are offered to them is integral to maintaining and improving the quality of healthcare systems. Understanding the diverse needs and perspectives of patients can help to inform healthcare decision-making and contribute to the transparency, accountability, and credibility of resource allocation across health systems. One such mechanism in the UK is Patient Participation Groups (PPGs): a group of patients, carers, and Primary Care staff who meet to discuss practice issues and the patient experience in order to improve the quality of the service.

Beyond primary care, patient and public participation in health system decision making helps to ensure that decisions about how to organise the healthcare system, and which treatments to fund, are as fair and as transparent as possible. Too often, however, HTA processes see patients primarily as study subjects rather than empowering them to play a meaningful role in decision-making processes. OHE supports and advocates for a greater role for patients, carers, and the public in HTA decision-making.

OHE has been involved in a number of projects that demonstrate the value of greater patient and public participation around health system decision making. A recent patient preference study found that people with experience of infertility were willing to forego some chance of a successful pregnancy to have a greater degree of shared decision-making in their treatment, highlighting opportunities to for patient input improve the process of treatment. Likewise, a willingness-to-pay study showed that the public across 8 countries was willing to contribute to a national infertility treatment programme, highlighting the opportunity for public preferences to shape policy. OHE is also involved in an ongoing study of patient preferences in the treatment of leukaemia. Recognition of patient preferences over their leukaemia treatment is often seen as secondary to maximising survival, and this study seeks to understand the priorities of different subgroups of persons with leukaemia. Such an understanding can help to ensure that healthcare is organised in a way that can address the full range of patient priorities.

 

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
Prize-hub-banner_1
  • News
  • May 2022

OHE Innovation Policy Prize

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 OHE

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!